Lecture by Dr. Patrick Treacy to the London Aesthetic Conference in 2008 about UltraShape, which uses the new process of therapeutic ultrasound to remove unwanted fat.

1. UltraShape® the evidence

4. Internationally How big is the problem?

6. SURGICAL +118% in 7 years

7. NON-SURGICAL +763% in 7 years

8. Recent explosion of non-surgical devices

9. Non-SURGICAL • Continue to grow quicker than surgical • >4 x more common than surgical – (ASAPS - USA 2004 12 million cosmetic procedures - 2,1 Surgical and 9,7 nonsurgical) • No or limited downtime • High patient acceptance

10. Surgical procedures are objective with previous defined parameters. Minimal outlay If done in hospital type setting

11. Problem… this has long downtime, higher morbidity and less patient acceptance

12. Key to success in any cosmetic procedure … . a well informed patient with realistic expectations

13. … to be able to inform patients correctly we have to know the potentials and limitations of a non surgical aesthetic procedure. Thus carefully controlled and monitored studies are needed regarding UltraShape…

14. UltraShape® The clinical evidence

19. UltraShape ® Multi-Center Controlled Clinical Trial Single-Treatment Teitelbaum et al. PRS Study Results Study Normal Pulse oximetry No treatment-induced change Liver ultrasound No clinically significant change Two-point discrimination

30. Measuring Parameters

32. Photos courtesy of Dr. Benjamin Ascher, Paris Pre-Treatment 3 months Post Treatment Reduction  5.0 cm Weight change  -1.0 kg Abdomen UltraShape ™ Three Treatment Results

34. Baseline Treated Area: Abdomen Circumference measure: 97.0 cm Weight 63.8 Kg 1 Mo FU after 3 Tx Treated Area: Abdomen Circumference measure: 92.5 cm Weight 61.9 Kg Circumference Reduction: 4.5 cm Courtesy of Hector Leal-Silva, MD Monterrey, Mexico Three Treatment Results

35. Baseline Treated Area: Abdomen Fat Layer Thick: 4.9 cm After 1 Tx Treated Area: Abdomen Fat Layer Thick: 4.5 cm Fat Thickness Reduction: .4 cm Courtesy of Hector Leal-Silva, MD Monterrey, Mexico One Treatment Results

36. Baseline Treated Area: Abdomen Fat Layer Thick: 4.9 cm After 2 Tx Treated Area: Abdomen Fat Layer Thick: 4.2 cm Fat Thickness Reduction: .7 cm Courtesy of Hector Leal-Silva, MD Monterrey, Mexico Two Treatment Results

37. 1 Mo FU after 3 Tx Treated Area: Abdomen Fat Layer Thick: 3.8 cm Baseline Treated Area: Abdomen Fat Layer Thick: 4.9 cm Circumference Reduction: 4.5 cm Fat Thickness Reduction: 1.1 cm Courtesy of Hector Leal-Silva, MD Monterrey, Mexico Three Treatment Results

38. Personal Clinical Experience July 2005 - October 2007 500+ Patient Treatments London Bridge Plastic Surgery

39. Three Treatment Results – All Sites After Three Treatments -7.5 cm

41. Photos courtesy of Dr. Chris Inglefield, London, UK Abdomen Pre-Treatment 1 month Post Treatment UltraShape ™ Single-Treatment Results Reduction  4.5 cm

42. Photos courtesy of Dr. Chris Inglefield, London, UK Abdomen Pre-Treatment 1 month Post Treatment UltraShape ™ Single-Treatment Results Reduction  1.8 cm

43. Photos courtesy of Dr. Chris Inglefield, London, UK Lower Abdomen Pre-Treatment Post Treatment UltraShape ™ Two Treatment Results Reduction  5.6 cm

44. Photos courtesy of Dr. Chris Inglefield, London, UK Lower Abdomen and Flanks Pre-Treatment Post Treatment UltraShape ™ Two Treatment Results Reduction  4.5 cm

45. Photos courtesy of Dr. Chris Inglefield, London, UK Pre-Treatment 1-month Post Treatment Reduction  6.7 cm Lower Abdomen UltraShape ™ Three Treatment Results

51. UltraShape ® CONTOUR 2 Patient Info Screen (Data Base) Zebra Cross (Determining the Shape of the Treatment Area) Selection of Boundaries of the Treatment Area Once area is detected, the number of nodes is displayed Markers Selection Treatment Blue indicates overlap of target and the center of the transducer; White X indicates good acoustic contact New Software and GUI

56. Teitelbaum et al. PRS Blood and urine analysis performed: days 0, 1, 3, 7, 14, 21, 28, 56, and 84 post treatment UltraShape ® Multi-Center Controlled Clinical Trial Single-Treatment Study Results Lab Study No clinically significant changes CBC No clinically significant changes PT, PTT, INR No clinically significant changes Electrolytes, BUN/Cr No clinically significant changes LFT’s, Bilirubin, Albumin No clinically significant changes Serum Lipids No clinically significant changes CPK, calcium No clinically significant changes Urinalysis